{
    "medicine_id": "4e410831dae0f6fea09256e072af786b27bc32d6",
    "platform_id": "DB15271",
    "metadata": {
        "name": "Adakveo 10 mg 1mL Injection",
        "composition": "10 mg 1mL Crizanlizumab",
        "clinical_particulars": {
            "therapeutic_indications": "Crizanlizumab is indicated to reduce the frequency of vaso occlusive crisis in patients with sickle cell diseases who are 16 years old L10097",
            "contraindications": {
                "disease": "Data regarding the toxicity of crizanlizumab is not readily available L10097",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Crizanlizumab is a P selectin inhibitor that prevents interactions between endothelial cells platelets red blood cells and leukocytes L10097 It has a long duration of action as it is given every 4 weeks L10097 Patients should be counselled regarding the risk of infusion reactions as well as crizanlizumab s interference with platelet counts using EDTA tubes L10097",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}